India’s Union Budget 2026–27 introduced a defining initiative for the life sciences sector: Biopharma SHAKTI.
More than a funding announcement, Biopharma SHAKTI represents a long-term structural strategy — one aimed at strengthening India’s position as a global hub for biologics and biosimilars, while deepening scientific, manufacturing, and clinical capabilities across the country.
This blog breaks down what Biopharma SHAKTI is, why it matters now, and what it signals for India’s evolving biopharma ecosystem.
What Is Biopharma SHAKTI?
Biopharma SHAKTI is a national strategy announced in the Union Budget 2026–27 with a planned ₹10,000 crore investment spread over five years.
The initiative is designed to:
- Position India as a global biopharma manufacturing hub
- Strengthen domestic capabilities in biologics and biosimilars
- Expand research, education, and clinical trial infrastructure
- Build scale with scientific credibility, not just volume
At its core, Biopharma SHAKTI focuses on advancing healthcare through knowledge, technology, and scale — recognizing that future leadership in biopharma depends on all three working together.
The need for Biopharma SHAKTI
India’s biopharma sector has matured rapidly over the past decade. However, growth has also exposed structural gaps:
- Heavy reliance on imported advanced biologics and critical tools
- Limited clinical trial infrastructure relative to demand
- Fragmented research-to-manufacturing pipelines
At the same time, the demand for biologics is accelerating globally — driven by rising non-communicable diseases, oncology therapies, autoimmune treatments, and complex biologic modalities.
Biopharma SHAKTI acknowledges a clear reality:
manufacturing scale alone is no longer enough.
Scientific depth, regulatory confidence, and ecosystem readiness now define global competitiveness.
Key Pillars of Biopharma SHAKTI
Biopharma SHAKTI is structured around four interconnected pillars:
1. Biologics & Biosimilars Manufacturing
The initiative aims to deepen domestic production capabilities for complex biologics and biosimilars — reducing dependence on imports while improving supply resilience and affordability.
2. Expanding Research & Innovation
Investment in research institutions, translational science, and advanced biotechnology education is central to building long-term scientific capacity.
This includes:
- Upgrading existing institutions
- Supporting advanced life-science education
- Encouraging translational research pathways
3. Scaling Clinical Trials
One of the most significant components is the planned development of 1,000+ accredited clinical trial sitesnationwide.
This expansion is expected to:
- Improve trial accessibility and speed
- Strengthen data quality and consistency
- Support complex biologic and biosimilar programs
4. Building an Integrated Ecosystem
Rather than isolated investments, Biopharma SHAKTI emphasizes ecosystem integration — aligning academia, industry, regulators, and infrastructure to work cohesively.
From Import Dependence to Indigenous Capability
Historically, many emerging biopharma ecosystems — including India’s — relied on imported biologics, assays, and advanced research tools to accelerate early growth.
Biopharma SHAKTI signals a deliberate shift:
from import reliance → to indigenous capability with global relevance.
This transition is not about replacing global collaboration.
It is about owning quality, consistency, and scientific accountability within the country.
Our Role in Indigenous Bioanalysis
At deNOVO Biolabs, the evolution toward indigenous capability has been central from the start.
As an Indian company developing ELISA kits and bioanalytical solutions for global PK and immunogenicity studies, deNOVO operates at the intersection of:
- Science
- Quality
- Regulatory readiness
By supporting multiple leading Indian biopharma companies with bioanalytical tools and services, deNOVO contributes to the ecosystem Biopharma SHAKTI aims to strengthen — one built on credible data, consistent performance, and local scientific ownership.
Biopharma SHAKTI sets the foundation for India to move from participation to leadership in global biopharma.
Its success will depend not only on policy execution, but on how effectively the ecosystem — industry, academia, and service partners — collaborates to translate investment into trusted science.
If you are building biologics or biosimilars, then let’s explore how we cam support you.